Selegiline for neuroleptic-induced parkinsonism.
Gewirtz
G R
GR
Department of Clinical Psychobiology-New York State Psychiatric Institute/Columbia University Department of Psychiatry.
Sharif
Z
Z
Cadet
J L
JL
Sarti
P
P
Gorman
J M
JM
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006220:Haloperidol / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000188:drug therapy*; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy; D012642:Selegiline / Q000627:therapeutic use*
D014150:Antipsychotic Agents; D012642:Selegiline; D006220:Haloperidol